TY - JOUR
T1 - Radiation-oncology horizon 2030
T2 - From microbiota to plasma laser
AU - Beaudelot, C.
AU - Bayart, E.
AU - Thariat, J.
AU - Bourgier, C.
AU - Denis, F.
AU - Hatt, M.
AU - Pasquier, D.
AU - Verry, C.
AU - Deutsch,
AU - Levy, A.
N1 - Publisher Copyright:
© 2020 Société française de radiothérapie oncologique (SFRO)
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Advances in physical, technological and biological fields have made radiation oncology a discipline in continual evolution. New current research areas could be implemented in the clinic in the near future. In this review in the form of several interviews, various promising themes for our specialty are described such as the gut microbiota, tumor organoids (or avatar), artificial intelligence, connected therapies, nanotechnologies and plasma laser. The individual prediction of the best therapeutic index combined with the integration of new technologies will ideally allow highly personalized treatment of patients receiving radiation therapy.
AB - Advances in physical, technological and biological fields have made radiation oncology a discipline in continual evolution. New current research areas could be implemented in the clinic in the near future. In this review in the form of several interviews, various promising themes for our specialty are described such as the gut microbiota, tumor organoids (or avatar), artificial intelligence, connected therapies, nanotechnologies and plasma laser. The individual prediction of the best therapeutic index combined with the integration of new technologies will ideally allow highly personalized treatment of patients receiving radiation therapy.
KW - Dose rate
KW - Intestinal flora
KW - Ionizing radiation
KW - Patient Reporting Outcomes (PROs)
KW - Radiomics
KW - Spheroid
UR - http://www.scopus.com/inward/record.url?scp=85089867332&partnerID=8YFLogxK
U2 - 10.1016/j.canrad.2020.06.023
DO - 10.1016/j.canrad.2020.06.023
M3 - Review article
C2 - 32861611
AN - SCOPUS:85089867332
SN - 1278-3218
VL - 24
SP - 744
EP - 750
JO - Cancer/Radiotherapie
JF - Cancer/Radiotherapie
IS - 6-7
ER -